Clinical Trials
2 trialsNCT03150056 2022-08-10
Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer
GlaxoSmithKline
Phase 1 Terminated
NCT02056392 2015-11-09
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
AstraZeneca
Phase 1 Completed